Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation

NCT04564313 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Liver Transplantation

Interventions

DRUG: Camrelizumab treatment

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University